The Canadian optimal therapy of COPD trial: Design, organization and patient recruitment

Canadian Respiratory Journal

Volumn 11, Issue 8, 2004, Pages 581-585

  Aaron, Shawn D ^a,h   Vandemheen, Katherine ^a   Ferguson, Dean ^a   FitzGerald, Mark ^b   Maltais, Francois ^c   Boureau, Jean ^d   Goldstein, Roger ^e   McIvor, Andrew ^f   Balter, Meyer ^e   O'Donnell, Denis ^g  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bronchodilators; Chronic obstructive lung disease; Emphysema; Inhaled corticosteroids

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALBUTAMOL; SALMETEROL XINAFOATE; STEROID; TIOTROPIUM BROMIDE;

ARTICLE; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DELIVERY SYSTEM; DYSPNEA; EXPERIMENTAL DESIGN; HEALTH CARE FACILITY; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HUMAN; INHALER; LUNG FUNCTION; MEDICAL RESEARCH; MEDICAL SOCIETY; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 19944427439     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/394710     Document Type: Article

References (26)

1. Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: A survey. Ann Pharmacother 1997;31:160-4.
2. O'Donnell DE, Aaron SD, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003. Can Respir J 2003;10(Suppl A):11A-65A.
3. Casaburi R, Mahler DA, Jones P, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
4. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
5. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
6. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9.
7. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
8. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-92.
9. Calverley P, Pauwels R, Vestbo J, et al; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003;361:449-56. Erratum in: 2003;361:1660.
10. Mahler DA, Wire F, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2002;166:1084-91.
11. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81. Erratum in: 2003;21:912
12. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124:834-43.
13. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159:156-60.
14. Chapman KR, Arvidsson P, Chuchalin AG, et al; International study group. The addition of salmeterol 50 μg bid to anticholinergic treatment in patients with COPD: A randomized, placebo controlled trial. Can Respir J 2002;9:178-85.
15. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878-85.
16. Canadian Institute for Health Information, Canadian Lung Association, Health Canada, and Statistics Canada. Respiratory Disease in Canada. Ottawa: Health Canada; 2001.
17. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Crit Care Med 2001;163:1256-76.
18. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 Suppl 2):398S-401S.
19. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
20. Pauwels R. Inhaled glucocortisteroids and chronic obstructive pulmonary disease. How full is the glass? Am J Resp Crit Care Med 2002;165:1579-80.
21. Anthonisen NR. Inhaled steroids in chronic obstructive pulmonary disease. Can Respir J 2002;9:11-2.
22. Miravitlles M, Murio C, Guerrero T, Gishert R; DAFNE (Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC) Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55.
23. Jones PW, Quirk FH, Baveystock CM, Littlejohns F. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
24. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
25. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
26. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-19.